Factor XIIIA is the active subunit of plasma factor XIII that is responsible for cross linking fibrin into a stable clot. Sixteen patients with Crohn's disease were studied prospectively from relapse (Crohn's disease activity index >150) into remission. Plasma factor XIIIA concentrations were significantly lower in active disease (median 63 (95% CI 46-72) U/dl) than remission (median 90 (95% CI 60-112) U/dl; p=0002). Plasma factor XIIIA concentrations correlated positively with the activity index (p=0005) and platelet count (p=0003), and negatively with serum albumin (p=0 006). In five patients with persistent aggressive disease, the factor XIIIA concentration remained below the lower range of normal despite apparent clinical improvement in response to medical treatment. Tissues from three patients who underwent surgical resection during the study were immunostained for factor XIIIA. Gut mucosal and submucosal macrophages stained strongly for factor XIIIA. In one patient, capillary thrombi near superficial mucosal erosions immunostained for factor XIIIA in macroscopicaily normal mucosa. Similar changes were identified in more severely inflamed sections ofintestine from the other two patients. The demonstration of significantly low plasma factor XIIIA concentrations in active Crohn's disease, and the immunostaining of factor XIIIA in capillary thrombi in the bowel wall, suggest that activation of coagulation may be involved in the pathogenesis of Crohn's disease. The plasma factor XIIIA concentration may prove a useful laboratory marker of disease activity.
M Hudson, A J Wakefield, R A Hutton, E A Sankey, A P Dhillon, L More, R Sim, R E Pounder Abstract Factor XIIIA is the active subunit of plasma factor XIII that is responsible for cross linking fibrin into a stable clot. Sixteen patients with Crohn's disease were studied prospectively from relapse (Crohn's disease activity index >150) into remission. Plasma factor XIIIA concentrations were significantly lower in active disease (median 63 (95% CI 46-72) U/dl) than remission (median 90 (95% CI 60-112) U/dl; p=0002). Plasma factor XIIIA concentrations correlated positively with the activity index (p=0005) and platelet count (p=0003), and negatively with serum albumin (p=0 006). In five patients with persistent aggressive disease, the factor XIIIA concentration remained below the lower range of normal despite apparent clinical improvement in response to medical treatment. Tissues from three patients who underwent surgical resection during the study were immunostained for factor XIIIA. Gut mucosal and submucosal macrophages stained strongly for factor XIIIA. In one patient, capillary thrombi near superficial mucosal erosions immunostained for factor XIIIA in macroscopicaily normal mucosa. Similar changes were identified in more severely inflamed sections ofintestine from the other two patients. The demonstration of significantly low plasma factor XIIIA concentrations in active Crohn's disease, and the immunostaining of factor XIIIA in capillary thrombi in the bowel wall, suggest that activation of coagulation may be involved in the pathogenesis of Crohn's disease. The (Table I) . At each hospital visit, the clinical details necessary to calculate the CDAI were recorded and blood samples were obtained for routine tests and factor XIII assay. After venepuncture, 9 ml blood were added to 1 0 ml 0 109 M trisodium citrate and centrifuged at 2000 xg for 15 mintues at 4°C. The resulting plasma was centrifuged as before and the supernatant was stored at -40°C until assayed. The factor XIIIA and S subunits were measured by the Laurell rocket electroimmunoassay," using monospecific antisera (Behring Diagnostics, Hounslow, UK). Results were expressed as a per cent of a pooled plasma standard from 20 healthy subjects.
Fibrinopeptide-A (Boehringer-Mannheim, Lewes, UK) and d-dimer (Porton, Newmarket, UK) were measured by enzyme linked immunoadsorbent assay (ELISA) as markers of fibrinogen cleavage and firinolysis respectively.3
Three patients underwent surgery during the course of the study. Immediately after resection, the specimens underwent arterial cannulation, heparin saline flush and perfusion fixation with 16 (Fig 1) . The The five patients with persistently low factor XIIIA concentrations are denoted with '*' and the two patients whose factor XIIIA concentrations rose only after surgery with '+'. P=prednisolone; MEZ=mesalazine; AZA=azathioprine; SSZ=sulphasalazine.
( Table) . Two ofthe nine patients who improved, Factor XIIIA assayed in 61 plasma samples has both in terms of CDAI and a sustained rise of a significant negative correlation with the CDAI factor XIIIA concentrations, did so only after (p=O0OO5) and platelet count (p=0003; Spearsurgery. None of the remaining seven patients man rank correlation test). There is a significant have required surgical intervention during 18 positive correlation between the factor XIIIA months of follow up. concentration and the serum albumin level, 
p=0-006 (Spearman rank correlation test).
There is no correlation with the C-reactive protein (p=0-319).
TISSUE LOCALISATION OF FACTOR XIIIA
Three patients underwent surgical intervention during the study. In areas of severe mucosal ulceration, in two ofthese cases (patients 2 and 6) and in the third case from an area showing epithelial erosion, lamina proprial haemorrhage, but no inflammation (patient 8), material immunostaining for factor XIIIA was present as plugs within or close to ruptured mucosal capillaries ( Figure 3A ). These plugs corresponded to eosinophilic 'fibrinoid' material seen after haematoxylin and eosin (Fig 3B) . They showed immunostaining for platelet glycoprotein IIIa (Fig 3C) . Factor XIIIA immunostaining of sections from all three resected bowel specimens in this study identified a population of dendritic cells scattered singly throughout the connective tissue of the bowel wall. These cells were more numerous in areas of chronic inflammation. Factor XIIIA positive cells occupied the lower mucosa and submucosa. They were observed in contact with other inflammatory cells (lymphocytes and plasma cells; Figure 4 ) and mast cells. They were often prominent around vessels of the submucosa, where they were present in the tunica adventitia. The authors suggested the factor XIII may be lost through a leaky mucosa, but factor XIII has a molecular weight of 320 000 daltons compared with albumin's 69 000 daltons. The lowest factor XIII concentrations were found in two patients with haemorrhagic Crohn's colitis; the authors suggest that the bleeding was because of low factor XIII concentrations and fragile clot. This suggestion conflicts with in vitro studies which show that only 10% or less of the factor XIIIA found in plasma is required for normal haemostasis. 20 Studies from Japan and Poland have shown low concentratons of factor XIIIA in active ulcerative colitis,2' 22 with apparent clinical and endoscopic improvement in one patient after treatment with recombinant factor XIIIA. 22 Similar falls in factor XIIIA have been noted in Henoch Schonlein purpura, a vasculitic syndrome characterised by fibrin deposition,23 involving skin, joints, kidneys, and the gastrointestinal tract. In addition to reflecting increased consumption -for example, in wound healing or disseminated intravascular coagulation'°-a low plasma factor XIIIA concentration may indicate decreased XIIIA synthesis as a result of chronic liver disease. None of the patients in this study had concurrent liver disease but fibrinopeptide-A and d-dimer concentrations were raised in the active phase of disease.
In conclusion, this study has identified both a deficiency of factor XIIIA subunit in the plasma of patients with active Crohn's disease, and deposition ofXIIIA in diseased intestinal tissues. Initial observations suggest that XIIIA may provide an additional marker of disease activity to the currently available clinical disease activity scores and the C-reactive protein.
